Internist/ Medical Oncologist Dr. Stefan F. Faderl MD – Clinical Researcher Of The Day
In today’s Clinical Researcher of the Day, we are highlighting physician-researcher, Dr. Stefan F. Faderl M D, an Associate Professor of Cancer Medicine in the Department of Leukemia in The University of Texas MD Anderson Cancer Center, Houston, TX. He received his education from Ludwig Maximilian Medical School in Munich, Germany in 1990 and received his medical/academic degree from the same institution in 1994. He is a Internist/ Medical Oncologist who specializes in the treatment of acute and chronic leukemias and his main fields of interest involve acute lymphoblastic leukemias (ALL), acute myeloid leukemias (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemias (CML).
UT MD Anderson Cancer Center Houston, Texas, United States, 77030
Achievements of Dr. Stefan F. Faderl
- Dr. Faderl is board certified in Internal Medicine and Medical Oncology.
- He is a member of several professional societies such as the American Society of Hematology (ASH).
- Dr. Faderl has authored and co-authored a lot of abstracts, articles in peer-reviewed journals and book chapters.
Dr. Stefan is currently involved in five clinical trials:
- Clofarabine Combinations in Relapsed/Refractory AML MDS and Myeloid Blast Phase CML: The purpose of this study is to better o find the best safe dose for 2 different drug combinations.
- Clofarabine plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline AML and High-Risk MDS: The purpose of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older.
- Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma: The purpose of this clinical research study is to learn the effectiveness of intensive chemotherapy sure in combination with nelarabine (followed by maintenance therapy) in the treatment of patients with T cel ALL and T cell lymphoblastic lymphoma.
- A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL) Non-Hodgkin’s Lymphoma (NHL) or Multiple Myeloma (MM): Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM.
- Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS): The purpose of this clinical research study is to learn if sequential administration of decitabine and clofarabine can help to control myelodysplastic syndrome (MDS) better than decitabine alone.